STOCK TITAN

Vanguard amends Schedule 13G/A after realignment (JAZZ)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Jazz Pharmaceuticals PLC: The Vanguard Group files an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock.

The amendment states that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will now report holdings separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; reported zero beneficial ownership for Jazz.

The filing lists Amount beneficially owned: 0 and Percent of class: 0%. It attributes the change to an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538 for separate reporting by subsidiaries.

Cash‑flow treatment or subsequent holder-level amounts are not included in the excerpt; subsequent filings from Vanguard subsidiaries may show holdings separately.






G50871105

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Does The Vanguard Group currently report ownership in JAZZ common stock?

No. The amendment reports 0 shares beneficially owned and 0% of the class. The filing attributes this to an internal realignment completed on January 12, 2026, after which certain subsidiaries report holdings separately.

Why did Vanguard amend its Schedule 13G/A for Jazz (JAZZ)?

Vanguard amended the filing due to an internal realignment on January 12, 2026. Under SEC Release No. 34-39538, certain Vanguard subsidiaries now report beneficial ownership separately, causing The Vanguard Group to report 0 shares in this amendment.

Does this amendment show any subsidiary holdings of Jazz by Vanguard?

No subsidiary holdings are listed in this excerpt. The amendment states subsidiaries will report separately in reliance on SEC Release No. 34-39538; specific subsidiary-level share counts are not included here.

Who signed the amended Schedule 13G/A for Vanguard regarding JAZZ?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/27/2026. The signature attests to the amendment content showing 0 shares and 0% ownership.

Does the amendment indicate any voting or dispositive power for Vanguard in JAZZ shares?

No. The filing lists sole voting power: 0, shared voting power: 0, sole dispositive power: 0, and shared dispositive power: 0. It reports no control over Jazz common stock in this amendment.
Jazz Pharmaceuticals Plc

NASDAQ:JAZZ

View JAZZ Stock Overview

JAZZ Rankings

JAZZ Latest News

JAZZ Latest SEC Filings

JAZZ Stock Data

11.64B
59.47M
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN